David Mocini

David Mocini


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DMDavid Mocini
David Mocini
SFStefania Angela Di Fusco
Stefania Angela Di Fusco
EMEdoardo Mocini
Edoardo Mocini
Lorenzo Maria DoniniLorenzo Maria Donini
Lorenzo Maria Donini
CLCarlo Lavalle
Carlo Lavalle
FCFurio Colivicchi
Furio Colivicchi
The use of the direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban (DOACs) offers some major advantages over warfarin and other vitamin K antagonists (VKAs). One advantage is the possibility to use a fixed dose in normal-weight patients, overweight patients and patients with obesity. However, the “one size fits all” strategy raised a concern regarding the possibility to undertreat patients with a high body mass index. No randomized controlled trials (RCTs) have ever compared VKAs and DOACs in this population. We analyzed data from the literature on DOAC pharmacokinetics and pharmacodynamics, results from the four pivotal phase III trials on non-valvular atrial fibrillation, retrospective observational studies and metanalyses. While we are aware of the limitation imposed by the absence of specific RCTs, we propose the position of the Italian Association of Hospital Cardiologists (ANMCO) on the use of DOACs in patients with obesity based on the existing evidence.